These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21209853)

  • 41. A novel interaction between HER2/neu and cyclin E in breast cancer.
    Mittendorf EA; Liu Y; Tucker SL; McKenzie T; Qiao N; Akli S; Biernacka A; Liu Y; Meijer L; Keyomarsi K; Hunt KK
    Oncogene; 2010 Jul; 29(27):3896-907. PubMed ID: 20453888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling.
    Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
    Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer.
    Choi JS; Kim KH; Oh E; Shin YK; Seo J; Kim SH; Park S; Choi YL
    Pathology; 2017 Oct; 49(6):618-626. PubMed ID: 28818465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
    Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
    Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
    Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
    Badache A; Hynes NE
    Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer.
    Huang F; Shi Q; Li Y; Xu L; Xu C; Chen F; Wang H; Liao H; Chang Z; Liu F; Zhang XH; Feng XH; Han JJ; Luo S; Chen YG
    Cancer Res; 2018 Nov; 78(21):6073-6085. PubMed ID: 30171053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer.
    Wang J; Ji H; Niu X; Yin L; Wang Y; Gu Y; Li D; Zhang H; Lu M; Zhang F; Zhang Q
    Dis Markers; 2020; 2020():6103542. PubMed ID: 32377271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells.
    Zhang P; Chen Y; Gong M; Zhuang Z; Wang Y; Mu L; Wang T; Pan J; Liu Y; Xu J; Liang R; Yuan Y
    Cell Physiol Biochem; 2018; 50(1):52-65. PubMed ID: 30326469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.
    Garcia-Recio S; Fuster G; Fernandez-Nogueira P; Pastor-Arroyo EM; Park SY; Mayordomo C; Ametller E; Mancino M; Gonzalez-Farre X; Russnes HG; Engel P; Costamagna D; Fernandez PL; Gascón P; Almendro V
    Cancer Res; 2013 Nov; 73(21):6424-34. PubMed ID: 24030979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage.
    Ju JH; Yang W; Oh S; Nam K; Lee KM; Noh DY; Shin I
    Biochem J; 2013 Apr; 451(1):123-34. PubMed ID: 23323858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.